Squarepoint Ops LLC Has $185,000 Holdings in Shattuck Labs, Inc. (NASDAQ:STTK)

Squarepoint Ops LLC lessened its stake in Shattuck Labs, Inc. (NASDAQ:STTK) by 17.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 47,975 shares of the company’s stock after selling 10,367 shares during the quarter. Squarepoint Ops LLC’s holdings in Shattuck Labs were worth $185,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Cannon Global Investment Management LLC acquired a new stake in shares of Shattuck Labs in the 1st quarter valued at approximately $91,000. Virtu Financial LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at $113,000. Susquehanna Fundamental Investments LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at $174,000. SG Americas Securities LLC lifted its holdings in Shattuck Labs by 4.8% during the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock valued at $352,000 after purchasing an additional 1,788 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Shattuck Labs during the 2nd quarter valued at $170,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on STTK shares. BTIG Research downgraded Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th. Citigroup cut Shattuck Labs from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Evercore ISI upgraded Shattuck Labs to a “strong-buy” rating in a research report on Wednesday, October 2nd. Needham & Company LLC cut Shattuck Labs from a “buy” rating to a “hold” rating and set a $8.00 price objective on the stock. in a research report on Wednesday, October 2nd. Finally, HC Wainwright cut Shattuck Labs from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 1st. Four analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.67.

Shattuck Labs Stock Performance

Shares of NASDAQ STTK opened at $1.54 on Monday. Shattuck Labs, Inc. has a 52 week low of $1.07 and a 52 week high of $11.76. The stock has a market capitalization of $73.23 million, a P/E ratio of -0.80 and a beta of 1.72. The stock’s fifty day moving average is $3.11 and its 200 day moving average is $5.64.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, August 1st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 68.65%. The business had revenue of $1.61 million during the quarter, compared to the consensus estimate of $0.50 million. The company’s revenue was up 704.5% compared to the same quarter last year. Equities research analysts forecast that Shattuck Labs, Inc. will post -1.56 earnings per share for the current year.

Insider Buying and Selling at Shattuck Labs

In other Shattuck Labs news, CEO Taylor Schreiber bought 36,500 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the completion of the transaction, the chief executive officer now directly owns 71,002 shares in the company, valued at approximately $85,912.42. The trade was a 100.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 10.50% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.